Abstract
Importance of the field:
New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials.
Areas covered in this review:
This review examines the preclinical and the published clinical data with regards to naptumomab.
What the reader will gain:
This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent.
Take home message:
Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / chemistry
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Drug Design
-
Enterotoxins / adverse effects
-
Enterotoxins / chemistry
-
Enterotoxins / pharmacokinetics
-
Enterotoxins / pharmacology
-
Enterotoxins / therapeutic use*
-
Humans
-
Immunoconjugates / adverse effects
-
Immunoconjugates / chemistry
-
Immunoconjugates / pharmacokinetics
-
Immunoconjugates / pharmacology
-
Immunoconjugates / therapeutic use*
-
Neoplasms / drug therapy*
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Enterotoxins
-
Immunoconjugates
-
naptumomab estafenatox